A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

José Baselga, Serafin M. Morales, Ahmad Awada, Joanne L. Blum, Antoinette R. Tan, Marianne Ewertz, Javier Cortes, Beverly Moy, Kathryn J. Ruddy, Tufia Haddad, Eva M. Ciruelos, Peter Vuylsteke, Scot Ebbinghaus, Ellie Im, Lamar Eaton, Kumudu Pathiraja, Christine Gause, David Mauro, Mary Beth Jones, Hope S. Rugo

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences